Form 4: Arbutus Biopharma Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Karen Sims, Chief Medical Officer of Arbutus Biopharma, sold 19,348 common shares on February 4, 2025, to satisfy tax obligations related to vesting restricted stock units.
Summary
- On February 4, 2025, Karen Sims, the Chief Medical Officer of Arbutus Biopharma Corp, sold 19,348 common shares of the company.
- The shares were sold at a price of $3.283 per share.
- This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on March 9, 2023.
- The purpose of the sale was to cover tax obligations arising from the vesting of previous grants of restricted stock units.
- Following the transaction, Karen Sims directly owns 106,194 common shares of Arbutus Biopharma Corp.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (stock sale for tax obligations) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based compensation like restricted stock units. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on insider information.
Key Dates
| Date | Description |
|---|---|
| 2023/03/09 | Date of adoption of the 10b5-1 trading plan |
| 2025/02/04 | Date of the stock sale transaction |
| 2025/02/05 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.